BioMaxima SA
WSE:BMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioMaxima SA
Operating Income
BioMaxima SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioMaxima SA
WSE:BMX
|
Operating Income
zł1.3m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mercator Medical SA
WSE:MRC
|
Operating Income
zł38.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-44%
|
CAGR 10-Years
10%
|
|
|
P
|
PZ Cormay SA
WSE:CRM
|
Operating Income
-zł2.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
See Also
What is BioMaxima SA's Operating Income?
Operating Income
1.3m
PLN
Based on the financial report for Dec 31, 2024, BioMaxima SA's Operating Income amounts to 1.3m PLN.
What is BioMaxima SA's Operating Income growth rate?
Operating Income CAGR 5Y
11%
Over the last year, the Operating Income growth was 6 626%. The average annual Operating Income growth rates for BioMaxima SA have been -55% over the past three years , 11% over the past five years .
